Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
TCGX ACQUISITION CORP
Acquired Company
TriGemX Bio
United StatesPalo AltoInformation TechnologySoftwareBiotechnologyHealth CareTherapeuticsDescription
TCGX Acquisition Corp. and TriGemX Bio have announced a business combination agreement to create a publicly listed company. Following the merger, TriGemX Bio will use the proceeds to fund the development of elismetrep for migraine treatment. The transaction is expected to be completed in the first quarter of 2027, subject to shareholder approvals. The Combined Company will trade on Nasdaq under the ticker symbol 'TGEM'.
Fundz sees it the moment TCGX ACQUISITION CORP makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired TriGemX Bio?
TriGemX Bio was acquired by TCGX ACQUISITION CORP, based in United States. The deal was reported on October 19, 2026. TCGX Acquisition Corp. is a Cayman Islands-based special purpose acquisition company (SPAC) focused on pursuing merger opportunities within the technology sector. TCGX ACQUISITION CORP is publicly traded (TCGX) and operates in Information Technology.
When did TCGX ACQUISITION CORP acquire TriGemX Bio?
TCGX ACQUISITION CORP's acquisition of TriGemX Bio was reported on October 19, 2026. TCGX Acquisition Corp. and TriGemX Bio have announced a business combination agreement to create a publicly listed company. Following the merger, TriGemX Bio will use the proceeds to fund the development of elismetrep for migraine treatment. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does TriGemX Bio do?
TriGemX Bio is a biotechnology company dedicated to developing elismetrep, a potential first-in-class treatment for migraine. The company focuses on innovative therapies for neurological diseases. It is privately held, operating in Biotechnology, and is based in Palo Alto.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.